Catalent Expert to Present Drug Delivery Solutions to Enhance Bioavailability of Poorly Soluble Drugs at the 4th Annual Drug Repositioning and R&D Enhancement Conference
Somerset, NJ, September 12, 2011 -- Jeffrey E. Browne, Ph.D., Technical Director, Pharmaceutical Softgel Business Development, Catalent Pharma Solutions, will be presenting “Recent Advances to Improve Drug Product Performance Using Drug Delivery Techniques” at the 4th Annual Drug Repositioning and R&D Enhancement Conference in Philadelphia, PA on Tuesday, September 13, 2011, at 11:00 am.
Dr. Browne will focus on several innovative drug delivery technologies and the value proposition they offer to patients and product marketers. Specifically, the presentation will discuss the value of softgel technologies in addressing challenges beyond solubility improvement including the permeation enhancement and targeted delivery of drugs. Additional value-add technologies that will be highlighted during his presentation include the utilization of Vegicaps® capsules for the modified release of poorly water soluble drugs, and the use of Zydis® ODT technology for the oral delivery of nanoparticles. Dr. Browne will conclude his presentation with the introduction of Catalent’s recently acquired OSDrC® Optidose technology for manufacture of differentiated tablet formulations.
Throughout his career, Dr. Browne has held various positions in pharmaceutical manufacturing & technical services, as well as drug delivery R&D, with a focus on topical, transdermal, inhalation, and oral liquid dosage forms. In 1994, Dr. Browne joined Catalent Pharma Solutions (formerly RP Scherer and Cardinal Health Pharmaceutical Technologies & Services) and has expanded his expertise in a variety of positions and sites including: VP Softgel R&D in St. Petersburg, FL; Executive Director & Division Head of Pharmaceutical Development in Research Triangle Park, NC; Director of Technical Services in St. Petersburg, FL; Account Director, Business Development; and most recently, Technical Director, Pharmaceutical Softgels. Dr. Browne holds his Ph.D. in Industrial & Physical Pharmacy from Purdue University. He is active in the American Association of Pharmaceutical Scientists (AAPS), serving on several Focus Group committees and has presented frequently at regional and national AAPS meetings. He also serves on the Industrial Advisory Board of the Dane O. Kildsig Center for Pharmaceutical Processing Research, a center which encourages cooperative research between academia and industry.
To arrange a follow-up interview with Dr. Browne, please contact Patricia McGee at email@example.com .
To learn more about Catalent’s softgel technologies, go to: www.catalent.com/offerings/manufacturing/oral-dose-forms/softgel-capsules .
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,200 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.